% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Steinacker:140376,
      author       = {Steinacker, Petra and Anderl-Straub, Sarah and
                      Diehl-Schmid, Janine and Semler, Elisa and Uttner, Ingo and
                      von Arnim, Christine A F and Barthel, Henryk and Danek,
                      Adrian and Fassbender, Klaus and Fliessbach, Klaus and
                      Foerstl, Hans and Grimmer, Timo and Huppertz, Hans-Jürgen
                      and Jahn, Holger and Kassubek, Jan and Kornhuber, Johannes
                      and Landwehrmeyer, Bernhard and Lauer, Martin and Maler,
                      Juan Manuel and Mayer, Benjamin and Oeckl, Patrick and
                      Prudlo, Johannes and Schneider, Anja and Volk, Alexander E
                      and Wiltfang, Jens and Schroeter, Matthias L and Ludolph,
                      Albert C and Otto, Markus and group, FTLDc study and
                      Albrecht, Franziska and Bisenius, Sandrine and Feneberg,
                      Emily and Haefner, Sibylle and Kasper, Elisabeth and
                      Kurzwelly, Delia and Lampe, Leonie and Levin, Johannes and
                      Lornsen, Finn and Luley, Maxine and Oberstein, Timo and
                      Pellkofer, Hannah and Prix, Catharina and
                      Richter-Schmidinger, Tanja and Roth, Nina and Sabri, Osama
                      and Schachner, Lisa and Schomburg, Robert and Schönecker,
                      Sonja and Schuemberg, Katharina and Spottke, Annika and
                      Teipel, Stefan and Wilken, Petra and Zech, Heike},
      title        = {{S}erum neurofilament light chain in behavioral variant
                      frontotemporal dementia.},
      journal      = {Neurology},
      volume       = {91},
      number       = {15},
      issn         = {0028-3878},
      address      = {[S.l.]},
      publisher    = {Ovid},
      reportid     = {DZNE-2020-06698},
      pages        = {e1390-e1401},
      year         = {2018},
      abstract     = {Objective: To determine the association of serum
                      neurofilament light chain (NfL) with functional
                      deterioration and brain atrophy during follow-up of patients
                      with behavioral variant frontotemporal dementia
                      (bvFTD).Methods: Blood NfL levels from 74 patients with
                      bvFTD, 26 with Alzheimer disease (AD), 17 with mild
                      cognitive impairment (MCI), and 15 healthy controls (Con) at
                      baseline and follow-up were determined and analyzed for the
                      diagnostic potential in relation to functional assessment
                      (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB],
                      frontotemporal lobar degeneration–related CDR-SOB,
                      Mini-Mental State Examination [MMSE]) and brain
                      volumetry.Results: At baseline, serum NfL level correlated
                      with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666,
                      p = 0.0003). Highest serum levels were observed in bvFTD (p
                      <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively).
                      Discrimination of bvFTD from Con/MCI/AD was possible with
                      $91\%/74\%/74\%$ sensitivity and $79\%/74\%/58\%$
                      specificity. At follow-up, serum NfL increased in bvFTD and
                      AD (p = 0.0039 and p = 0.0006, respectively). At baseline
                      and follow-up, NfL correlated with functional scores of
                      patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p
                      = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with
                      atrophy in the gray and white matter of many brain regions
                      including frontal and subcortical areas (e.g., frontal lobe:
                      r = −0.5857, p < 0.0001; $95\%$ confidence interval
                      −0.7415 to −0.3701). For patients with AD/MCI, NfL
                      correlated with the functional performance as well (e.g.,
                      CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r =
                      0.5659, p = 0.0003) but not with regional brain
                      volumes.Conclusions: As serum NfL correlates with functional
                      impairment and brain atrophy in bvFTD at different disease
                      stages, we propose it as marker of disease severity, paving
                      the way for its future use as outcome measure for clinical
                      trials.Classification of evidence: This study provides Class
                      III evidence that for patients with cognitive problems,
                      serum NfL concentration discriminates bvFTD from other forms
                      of dementia.},
      keywords     = {Aged / Alzheimer Disease: blood / Alzheimer Disease:
                      cerebrospinal fluid / Alzheimer Disease: diagnostic imaging
                      / Alzheimer Disease: genetics / Atrophy / Biomarkers: blood
                      / Biomarkers: cerebrospinal fluid / Brain: pathology /
                      Cognitive Dysfunction: blood / Cognitive Dysfunction:
                      cerebrospinal fluid / Cognitive Dysfunction: diagnostic
                      imaging / Cognitive Dysfunction: genetics / Diagnosis,
                      Differential / Disease Progression / Female / Follow-Up
                      Studies / Frontotemporal Dementia: blood / Frontotemporal
                      Dementia: diagnostic imaging / Frontotemporal Dementia:
                      genetics / Frontotemporal Dementia: pathology / Humans /
                      Male / Middle Aged / Mutation / Neurofilament Proteins:
                      blood / Organ Size / Prospective Studies / Biomarkers (NLM
                      Chemicals) / Neurofilament Proteins (NLM Chemicals) /
                      neurofilament protein L (NLM Chemicals)},
      cin          = {AG Teipel / AG Wiltfang},
      ddc          = {610},
      cid          = {I:(DE-2719)1510100 / I:(DE-2719)1410006},
      pnm          = {344 - Clinical and Health Care Research (POF3-344) / 342 -
                      Disease Mechanisms and Model Systems (POF3-342)},
      pid          = {G:(DE-HGF)POF3-344 / G:(DE-HGF)POF3-342},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30209235},
      doi          = {10.1212/WNL.0000000000006318},
      url          = {https://pub.dzne.de/record/140376},
}